Pet ODT supplements — orally disintegrating tablets and oral dissolvable films — solved a delivery problem in pet nutrition. They did not solve the paperwork. A pet nutritional ODT has to clear a facility-registration regime, a materials-and-safety documentation regime, a manufacturing-oversight regime, and a labelling-and-claims regime, and those four regimes do not line up neatly across borders.

This guide is written for exporters, brand owners and distributors who are evaluating a pet oral film supplier and need to know what “compliant” actually requires. It uses the Novohope oral film range — and specifically the FIT+ weight-management ODT supplied at 10 pcs per pack — as a working case. It describes only documents and specifications that appear in the manufacturer's verified record. Where a market expectation is not evidenced in that record, it is presented as a buyer-side verification step rather than as an established rule.

Why an ODT Creates Compliance Work That a Chew Does Not

The compliance burden of a pet ODT is not a marketing problem; it is a materials and record-keeping problem. Five variables change the moment a supplement becomes a fast-dissolving film or tablet:

• The film matrix is a material, not a carrier. Because the strip is swallowed rather than chewed and discarded, the matrix itself sits in a food-contact and ingestion pathway, and the documentation that supports it is a materials question.
• Disintegration is a performance characteristic. Third-party market analysis of oral dissolvable film technology reports disintegration times below 25 seconds and taste-masking palatability improvements of up to 47%, which is precisely why the format is attractive — and why buyers now ask for evidence rather than description.
• Unit count becomes a label fact. A 10-piece pack is a countable, declarable quantity. Pack format is read by regulators, retail buyers and consumers simultaneously.
• Claims outlive formulas. “Weight management” is a claim, not a specification. It has to be worded market by market even when the formulation behind it never changes.
• The document set is perishable. Registration and test records carry issue and validity dates, so a compliant shipper in one quarter is an unverified one in the next.

Industry Background: Growth That Is Outrunning Regulatory Clarity

The commercial case for getting compliance right is straightforward. Grand View Research values the global pet supplements market at approximately USD 2.8 billion in 2025, with projected growth to USD 4.6 billion by 2033, and places North America at 48.1% of global revenue share in 2025. Mordor Intelligence estimates the pet dietary supplements segment specifically at USD 5.11 billion by 2026, growing at a CAGR of 7.42% through 2031, and identifies Asia-Pacific as the fastest-growing region.

Those figures are reported on different classification bases — pet supplements versus pet dietary supplements — which is why 2025 estimates for the same category range from USD 2.8 billion to USD 4.76 billion depending on the agency. The divergence is not a flaw in the data; it is a signal for buyers. If the analysts cannot agree on where the category boundary sits, exporters should expect market authorities to draw that boundary differently as well.

Meanwhile the format itself keeps evolving. Oral dissolvable film technology is being adapted to the pet sector with short disintegration targets and palatability improvements, and the best-selling dog tear stain formulas on major e-commerce platforms can reach monthly volumes of 100,000 units, driven largely by specific antioxidant blends. Fast formats plus concentrated functional claims plus cross-border e-commerce is exactly the combination that turns a documentation gap into a shipment hold.

What “Compliance” Actually Covers for a Pet Nutritional ODT

Compliance for a pet oral dissolvable product is assembled from four building blocks. Each can be evidenced; each can also be missing.

1. Facility and establishment records

The verified record for this product family includes an FDA Food Facility Registration, number 18753066908, issued to Wuxi Nuohui Biotechnology Co., Ltd. on 1 July 2026, with recorded validity to 31 December 2026. A separate Certificate of FDA Registration, also numbered 18753066908, was issued on 2 July 2026 under Section 305 of the US Public Health Security and Bioterrorism Preparedness and Response Act of 2002. In the European Union, no equivalent EU-issued facility document appears in this record — a gap that has to be closed with the importer rather than assumed.

2. Ingredient and safety documentation

Safety Data Sheets prepared to the OSHA Hazard Communication Standard 29 CFR 1910.1200 are on file for COAT+ (DTI2026EC060626-1), EYES+ (DTI2026EC060626-2) and BONE+ (DTI2026EC060626-5), all issued 6 July 2026 by Shenzhen Deesev Testing International Corporation. Full ingredient composition test reports exist for COAT+ (DTI2026EC050626-1) and HEART+ (DTI2026EC050626-4), covering the client-designated test items.

3. Contact-material and packaging evidence

Contact materials are where oral films separate from conventional supplements. A test report covering EYES+ (DTI2026EC050626-2-2) was assessed to US FDA 21 CFR 175.300, the US framework for resinous and polymeric coatings. This is the class of evidence a US buyer should ask for by name, because it addresses the film and its packaging interface rather than the actives.

4. Manufacturing oversight, claims and IP

Manufacturing oversight in this record is defined as 100% full inspection before delivery plus third-party authoritative sampling testing — a two-layer acceptance model rather than a single end-of-line check. On the intellectual-property side, China trademark application acceptance notices were issued by the National Intellectual Property Administration on 12 February 2026: numbers 89737105 and 89737106 for Class 31, and 89737107 and 89737108 for Class 7. These are acceptances of applications, not granted registrations, and should be described as such in any buyer-facing document.

Finally, buyers in the United States frequently ask about the NASC Quality Seal, an industry standard that requires adherence to Good Manufacturing Practices and rigorous labelling audits. It is worth stating clearly: an NASC seal is a separate, voluntary verification and is not implied by an FDA facility registration. If your retail channel requires it, treat it as its own line item in supplier qualification.

US Versus EU: Where the Two Rulebooks Diverge

The United States and the European Union do not merely apply different thresholds; they begin from different premises. US market access for pet nutritional products leans on facility registration plus labelling and advertising scrutiny, with safety data and contact-material testing as supporting evidence. EU market access is assessed through feed legislation, where ingredients that fall into the feed-additive category depend on their authorisation status at EU level, and where labelling must satisfy the expectations of the individual member state.

The practical consequence for an exporter is that an ODT cannot be “globally certified” in one action. It can only be documented market by market. The table below maps where documented evidence exists and where buyer-side confirmation is required.

FIT+ as a Case Study: One Weight-Management ODT, Two Rulebooks

FIT+ is Novohope's pet weight management supplement, supplied in ODT (orally disintegrating tablet) form with a fast-dissolving matrix and weight management ingredients, at a specification of 10 pcs per pack. It is a useful case because “weight management” is the type of claim that regulators read differently from one jurisdiction to the next, while the physical product does not change at all.

Move 1: Fix the unit count, not the marketing story

Ten pieces per pack is a declarable, repeatable quantity. It gives the label a stable net-content statement, gives the batch record a stable counting unit, and gives retail buyers a comparable format. When a market or retail chain needs a different pack count, the format is adapted through packaging design — which sits inside the manufacturer's documented customization scope alongside recipe and brand — rather than by reformulating the tablet.

Move 2: Separate the claim from the formula

The formula is fixed; the wording around it is not. Keeping the tablet identical across markets means the same composition report, the same acceptance criteria and the same batch logic travel with it, while the claim text is reviewed market by market. This is the cheapest compliant position available to a brand owner: one product, several label variants, one evidence file.

Move 3: Keep evidence batch-linked

Acceptance is defined as 100% full inspection before delivery plus third-party authoritative sampling testing, with a COA quality report. For a weight-management SKU crossing several borders, that structure matters more than any single certificate, because it produces a per-batch record that can be re-presented to a new importer without renegotiating the whole supply relationship.

Step-by-Step: Building a Compliance-Aligned ODT Order

1. Classify the product and the market first. Decide whether the SKU is being placed as a pet nutritional product or as an animal feed item, and in which jurisdiction. Everything downstream — documents, labels, claims — follows from that decision.
2. Freeze the formula and the claim wording separately. The formulation is a technical document; the claim is a regulatory one. Approve them as two separate deliverables.
3. Assemble the facility and safety file. FDA Food Facility Registration 18753066908 (validity recorded to 31 December 2026), the Certificate of FDA Registration dated 2 July 2026, and the SDS documents for COAT+, EYES+ and BONE+ issued 6 July 2026.
4. Validate the film matrix and packaging evidence. Confirm that the substrate named in the EYES+ test report under US FDA 21 CFR 175.300 matches the commercial pack you intend to ship.
5. Lock the pack format and label. For FIT+, that means the 10 pcs configuration and the corresponding net-content declaration, adapted per market through packaging design.
6. Agree acceptance criteria in writing. Pre-shipment full inspection plus third-party authoritative testing and a COA quality report.
7. Schedule production against realistic timelines. Documented OEM/ODM minimum order quantity is 3,000 units per SKU, monthly capacity is 200,000,000 units, and lead time is 35–45 days.
8. Diarise every validity date. Registration and test records expire. A shipment scheduled after a lapse is a shipment that will be questioned.

Use Cases: Where Compliance-Aligned ODTs Actually Get Tested

Retail chain private label across several jurisdictions

The documented case for this product family is European private-label production combined with ODM customized formula development for buyers in Germany, the United Arab Emirates, Canada, Australia, France and the United States — a volume of 200,000 units delivered over three years into chain supermarkets and retail stores, with reported growth in the pet health category, favourable market feedback and stable repeat orders. The compliance lesson is structural: a private-label programme spanning six buyer countries cannot rely on a single certificate pack, because each importer re-presents the evidence to its own authority.

Distributors carrying a multi-SKU functional range

A distributor selling across coat, eye, joint, cardiac, digestive, calming and weight management categories needs one evidence library that covers the whole family rather than seven separate files. In this record, COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO and FIT+ are documented as a single product family with shared acceptance criteria.

Format migration from chew to ODT

Brands moving from soft chews to fast-dissolve formats usually underestimate one item: the contact-material question. Migration projects should budget for a new substrate test rather than assuming the chew's documentation carries over.

Functional lines with premium positioning

Premium functional categories such as tear stain formulas carry higher claim scrutiny. The EYES+ documentation — SDS plus a test report assessed to US FDA 21 CFR 175.300 — shows the evidence pattern a premium functional SKU should be able to produce on request.

The Verified Document Set Behind This Guide

The table below lists the compliance documents referenced throughout this article, exactly as recorded.

FAQ: Compliance, Capability, Cost, Samples and Lead Time

Which compliance documents does the manufacturer hold for pet oral film and ODT supplements?

The verified set contains an FDA Food Facility Registration, number 18753066908, issued to Wuxi Nuohui Biotechnology Co., Ltd. on 1 July 2026 with recorded validity to 31 December 2026; a Certificate of FDA Registration dated 2 July 2026 issued under Section 305 of the US Public Health Security and Bioterrorism Preparedness and Response Act of 2002; Safety Data Sheets prepared to OSHA Hazard Communication Standard 29 CFR 1910.1200 for COAT+, EYES+ and BONE+; full ingredient composition test reports for COAT+ and HEART+; a test report for EYES+ assessed to US FDA 21 CFR 175.300; and China trademark application acceptance notices 89737105 and 89737106 (Class 31) and 89737107 and 89737108 (Class 7), all dated 12 February 2026. No EU-issued authorisation appears in that set, so EU requirements must be confirmed with the importing party.

Can the formula, brand and packaging be customized for a specific market?

Yes. The documented customization scope covers recipe, brand, packaging design and other customized requirements, and the production model covers brand agency, distribution and OEM/ODM services. This is how a fixed ODT formula is adapted to market-specific pack counts, label languages and retail formats without changing the tablet itself.

What is the minimum order quantity for an OEM/ODM pet ODT project?

The documented OEM/ODM minimum order quantity is 3,000 units per SKU, against a monthly production capacity of 200,000,000 units. A sample-scale procurement profile is also documented at a minimum of 1 unit with DDP delivery, pre-shipment full inspection plus third-party authoritative testing and a COA quality report, settled by full payment before shipment. A larger profile is documented at 1,000 boxes per SKU with FOB/CIF delivery, pre-shipment testing and 50/50 payment terms. Confirm which profile applies to your order before internal quoting.

Can a buyer validate compliance evidence before committing to full production?

Yes. Samples, test reports and a COA quality report can be reviewed before a production order is placed; delivery acceptance is defined as 100% full inspection before shipment plus third-party authoritative sampling testing. Buyers evaluating a weight-management ODT such as FIT+ should request three documents together — the current SDS, the ingredient composition report and the contact-material test report — because each answers a different question and none substitutes for the others.

What is the production lead time, and what should buyers watch on document validity?

Documented production lead time is 35–45 days. Compliance documents run on their own clocks: the FDA Food Facility Registration in this record shows recorded validity to 31 December 2026, while the SDS and test reports carry 6 July 2026 issue dates. Buyers should confirm that the version supplied with the order is the current one at the time of shipment. To begin an evaluation, request the current document pack, a 10-piece FIT+ sample or a market-specific quotation through Novohope.

Conclusion: Compliance Is a File, Not a Certificate

For pet ODT and oral dissolvable film supplements, the honest answer to “is it compliant?” is another question: in which market, for which claim, against which document version? The US and EU pathways start from different premises — facility registration and labelling scrutiny on one side, feed legislation and additive authorisation on the other — and no single certificate bridges them.

What does bridge them is a disciplined file: a current facility registration, a safety data sheet that matches the product and its issue date, a contact-material test report that matches the actual substrate, an agreed acceptance model built on full inspection plus third-party testing, and claim wording reviewed market by market. Novohope's documented position on those five items — with FIT+ as the weight-management case and the 10 pcs pack as the fixed unit count — shows what that file looks like in practice.

Next Step: Request the Document Pack

If you are aligning a pet nutritional ODT with FDA and EU requirements, start with the evidence rather than the price list. Request the current document pack for your SKU, a 10-piece FIT+ sample for evaluation, or a quotation for a defined market — including the customization scope you need on recipe, brand and packaging. Contact the team via novohope.com and specify your target market and pack format so the right documents travel with the quote.